Immunotherapeutic Agent

PreclinicalSmall molecule

CCliniques universitaires Saint-Luc- Université Catholique de Louvain

Immunotherapeutic Agent is one of 55 small molecule programs targeting Metastatic Malignant Neoplasm. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Malignant NeoplasmActive, not recruiting

ImmunotherapyActive, not recruiting

Metastatic Malignant NeoplasmPreclinical

Active, not recruiting

ImmunotherapyPreclinical

Active, not recruiting

Competition

Competitive Landscape

84 competitors in Immunotherapy

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

22 2

Keytruda

Merck & Co.

Phase 3

18 3

Tecentriq

Roche

Phase 3

10 4

Taxol

Teva

Phase 3

3 5

Gazyva

Roche

Phase 3

1 6

Venclexta

AbbVie

Phase 3

1 7

Calquence

AstraZeneca

Phase 3

1 8

Paraplatin

AAvyxa

Phase 3

6 9

Yervoy

Bristol-Myers Squibb

Phase 2

8 10

Imfinzi

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

N/AActive, not recruiting

Immunotherapy

NCT03835520

Q3 2028

PreclinicalActive, not recruiting

Metastatic Malignant Neoplasm

NCT04150939

Q4 2035

Recruiting

Sarcoma

NCT03978039

Clinical

Trials by Indication[1]

Immunotherapy1 trial

Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy

Active, not recruiting·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·N/A·NCT03835520·200 enrolled

Sarcoma1 trial

National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group

Recruiting·IInstitut Bergonié··NCT03978039·150,000 enrolled

Immunochemotherapy1 trial

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Unknown status·ZZhejiang Cancer Hospital·Phase 3·NCT06031597·105 enrolled

Metastatic Malignant Neoplasm1 trial

Cryoablation Challenge Evaluated in Adaptive-Immune Resistance (CEDAR)

Active, not recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT04150939·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Immunotherapeutic Agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunotherapeutic Agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunotherapeutic Agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cliniques universitaires Saint-Luc- Université Catholique de Louvain company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCliniques universitaires Saint-Luc- Université Catholique de Louvain

Immunotherapeutic Agent

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q4 2035

Trials by Indication[1]

Immunotherapy1 trial

Sarcoma1 trial

Immunochemotherapy1 trial

Metastatic Malignant Neoplasm1 trial

References

Drug Info

Quick Facts

Related News